Inflammatory factors linked to inhibition of factor VIII gene therapy in hemophilia A

December 8, 2017, Mary Ann Liebert, Inc
Credit: Mary Ann Liebert, Inc., publishers

As a gene therapy cure for hemophilia A moves closer to reality, a new study sheds light on a challenging complication in which a host autoimmune response inhibits the production of normal clotting factor VIII from the transferred FVIII gene. Researchers compared the levels of multiple pro- and anti-inflammatory cytokines in a mouse model of hemophilia A that received FVIII gene therapy at different ages and either did or did not exhibit FVIII inhibitor formation, as presented in an article published in Human Gene Therapy.

The article entitled "A Retrospective Study of Cytokine Profiles Changes in Mice with FVIII Inhibitor Development after Adeno-Associated Virus-Mediated Gene Therapy in a Hemophilia A Mouse Model" is coauthored by Junjiang Sun, Gene Therapy Center and Eshelman School of Pharmacy, University of North Carolina (UNC, Chapel Hill), and colleagues from UNC, University of Saint Joseph School of Pharmacy (Hartford, CT), Northern Jiangsu People's Hospital (Yangzhou, China), Chinese Academy of Medical Sciences, and Peking Union Medical College (Beijing, China). The researchers reported a shift in the cytokine profiles of mice with FVIII inhibitor development, including significantly increased levels of pro-inflammatory cytokines such as interleukin (IL)-1 and IL-6 and tumor necrosis factor (TNF)-alpha, among others. They also showed a negative correlation between risk factors for FVIII inhibitor development and age at which gene therapy was administered.

"Immune responses represent an important limitation to gene therapy for hemophilia," says Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Worcester, MA. "The paper from Dr. Sun's group and their colleagues begins to address factors that may predispose certain individuals to mount a greater immune response against the therapeutic protein produced by the gene therapy vectors and thus benefit less from the ."

Explore further: Researchers improve vbectors for delivering hFVIII gene therapy to treat Hemophilia A

More information: Junjiang Sun et al, A Retrospective Study of the Cytokine Profile Changes in Mice with FVIII Inhibitor Development After Adeno-Associated Virus–Mediated Gene Therapy in a Hemophilia A Mouse Model, Human Gene Therapy (2017). DOI: 10.1089/hum.2017.094

Related Stories

Researchers improve vbectors for delivering hFVIII gene therapy to treat Hemophilia A

March 31, 2017
A new study examined 42 combinations of promoters and enhancers for human factor VIII (hFVIII) gene expression to identify the optimal adeno-associated virus (AAV)-based gene therapy delivery vector constructs to take forward ...

Mini form of replacement gene can delay degeneration in leber congenital amaurosis

October 5, 2017
A new study demonstrates success in using a shortened form of the CEP290 gene for gene therapy in a mouse model of Leber congenital amaurosis type 10 (LCA10), a retinal degenerative disorder that causes childhood blindness. ...

Gene therapy for liver disease advancing with the help of adeno-associated viral vectors

December 30, 2016
Liver-directed gene therapy delivered using adeno-associated viral (AAV) vectors to treat diseases such as hemophilia have advanced into human testing. The potential for continued technological improvements to expand the ...

In crafting new treatments for hemophilia, a 'less is more' approach

October 17, 2016
Hematology researchers have found that blocking the role of a common protein may offer unexpected benefits for patients with the inherited bleeding disorder hemophilia A. The finding offers potential for developing both gene ...

Prednisone may improve effectiveness of AAV-based gene therapy by reducing immune response

June 9, 2017
A new study of gene transfer using adeno-associated virus (AAV)-based gene delivery into skeletal muscle of rhesus macaques showed that oral prednisone reduced immune responses to AAV that can weaken expression of the therapeutic ...

Will AAV vectors have a role in future novel gene therapy approaches?

March 20, 2017
Recombinant adeno-associated virus (rAAV) vectors for delivering therapeutic genes have demonstrated their safety in multiple diseases and clinical settings over the years and are a proven and effective tool that can be used ...

Recommended for you

Gene editing possible for kidney disease

November 16, 2018
For the first time scientists have identified how to halt kidney disease in a life-limiting genetic condition, which may pave the way for personalised treatment in the future.

Progress in genetic testing of embryos stokes fears of designer babies

November 16, 2018
Recent announcements by two biotechnology companies have stoked fears that designer babies could soon be an option for those who can afford to pick and choose which features they want for their offspring. The companies, MyOme ...

DICE: Immune cell atlas goes live

November 15, 2018
Compare any two people's DNA and you will find millions of points where their genetic codes differ. Now, scientists at La Jolla Institute for Immunology (LJI) are sharing a trove of data that will be critical for deciphering ...

Ashkenazi Jewish founder mutation identified for Leigh Syndrome

November 15, 2018
Over 30 years ago, Marsha and Allen Barnett lost their sons to a puzzling childhood disease that relentlessly attacked their nervous systems and sapped their energy. After five-year-old Chuckie died suddenly in 1981, doctors ...

Drug candidate may recover vocal abilities lost to ADNP syndrome

November 15, 2018
Activity-dependent neuroprotective protein syndrome (ADNP syndrome) is a rare genetic condition that causes developmental delays, intellectual disability and autism spectrum disorder symptoms in thousands of children worldwide. ...

The puzzle of a mutated gene lurking behind many Parkinson's cases

November 15, 2018
Genetic mutations affecting a single gene play an outsized role in Parkinson's disease. The mutations are generally responsible for the mass die-off of a set of dopamine-secreting, or dopaminergic, nerve cells in the brain ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.